A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL)

Chadi Nabhan*, David Patton, Leo I. Gordon, Mary B. Riley, Timothy Kuzel, Martin S. Tallman, Steven T. Rosen

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

62 Scopus citations

Fingerprint

Dive into the research topics of 'A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL)'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science